

June 30, 2021

Boehringer Ingelheim Contract Pharmacy Policy Effective August 1, 2021

Dear 340B Covered Entity:


I am writing to inform you that Boehringer Ingelheim Pharmaceuticals, Inc. (BI) is altering its approach to distributing products purchased at the 340B price. For orders placed on or after August 1, 2021, except as provided below, BI will ship products purchased at the 340B price exclusively to locations registered as a 340B covered entity or their child site locations and will not facilitate shipment to commercial contract pharmacies.

To ensure that all 340B covered entities and their patients continue to have access to life-enhancing products purchased at the 340B price, BI will voluntarily apply the following general exceptions to its approach:


- First, any covered entity that does not have an in-house pharmacy capable of dispensing 340B purchased drugs to its patients may designate a single contract pharmacy location to receive and dispense 340B purchased products. BI is utilizing the 340B ESP™ platform to support this designation. 340B covered entities that do not have an in-house pharmacy, and have not already registered an account with 340B ESP™, can make their designations by visiting www.340besp.com/designations. Users that have registered an account with 340B ESP™ can designate a single contract pharmacy by navigating to the Entity Profile tab. If you have questions regarding the change in our 340B distribution model, please contact us at support@340Besp.com.
- Second, covered entities that are Federal grantees for medically underserved populations, and eligible for 340B participation under 42 U.S.C. § 256B(a)(4)(A)-(K), will remain eligible to place “Bill To / Ship To” replenishment orders of 340B priced drugs for their multiple pharmacies.
- Third, contract pharmacies that are wholly owned by a 340B hospital, or are under common ownership with a 340B health system, will remain eligible to receive “Bill To / Ship To” replenishment orders of 340B priced drugs. These pharmacies must be registered with HRSA as a contract pharmacy of their related 340B hospitals. To apply for a wholly owned contract pharmacy exemption, please reach out to support@340besp.com.

In support of a smooth transition to our new distribution model, 340B covered entities should work with their contract pharmacy administrators and wholesalers to process any outstanding “Bill To / Ship To” replenishment orders in advance of the August 1, 2021 effective date. PHS contracts administered by our wholesalers will no longer support distribution of 340B purchased drugs to 340B contract pharmacies after August 1, 2021.

Best regards,



Yew Looi Liew
President U.S. Human Pharma
Boehringer Ingelheim Pharmaceuticals, Inc.



Christine Marsh
Senior Vice President, Market Access
Boehringer Ingelheim Pharmaceuticals, Inc.